Scinai Immunotherapeutics Ltd (SCNI) - Total Assets
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) holds total assets worth $17.59 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Scinai Immunotherapeutics Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Scinai Immunotherapeutics Ltd - Total Assets Trend (2000–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See Scinai Immunotherapeutics Ltd book value and equity for net asset value and shareholders' equity analysis.
Scinai Immunotherapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Scinai Immunotherapeutics Ltd's total assets of $17.59 Million consist of 17.7% current assets and 82.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.3% |
| Accounts Receivable | $168.00K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Scinai Immunotherapeutics Ltd (SCNI) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scinai Immunotherapeutics Ltd's current assets represent 17.7% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2025, down from 100.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Scinai Immunotherapeutics Ltd Competitors by Total Assets
Key competitors of Scinai Immunotherapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Scinai Immunotherapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 0.71 | 0.61 |
| Quick Ratio | 1.35 | 0.71 | 0.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $929.01K | $-614.00K | $-8.24 Million |
Scinai Immunotherapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Scinai Immunotherapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -13.5% |
| Total Assets | $11.63 Million |
| Market Capitalization | $1.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scinai Immunotherapeutics Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scinai Immunotherapeutics Ltd's assets decreased by 13.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scinai Immunotherapeutics Ltd (2000–2025)
The table below shows the annual total assets of Scinai Immunotherapeutics Ltd from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.63 Million | -13.55% |
| 2024-12-31 | $13.45 Million | -23.03% |
| 2023-12-31 | $17.47 Million | -35.45% |
| 2022-12-31 | $27.07 Million | -15.51% |
| 2021-12-31 | $32.04 Million | +80.93% |
| 2020-12-31 | $17.71 Million | -47.17% |
| 2019-12-31 | $33.52 Million | +18.43% |
| 2018-12-31 | $28.30 Million | +20.54% |
| 2017-12-31 | $23.48 Million | +200.42% |
| 2016-12-31 | $7.82 Million | -26.28% |
| 2015-12-31 | $10.60 Million | +123.73% |
| 2014-12-31 | $4.74 Million | -36.37% |
| 2013-12-31 | $7.45 Million | +19.63% |
| 2012-12-31 | $6.22 Million | -13.10% |
| 2011-12-31 | $7.16 Million | -17.47% |
| 2010-12-31 | $8.68 Million | -3.02% |
| 2009-12-31 | $8.95 Million | +179.92% |
| 2008-12-31 | $3.20 Million | +440.12% |
| 2007-12-31 | $592.00K | -70.16% |
| 2006-12-31 | $1.98 Million | -40.69% |
| 2005-12-31 | $3.35 Million | -35.05% |
| 2004-12-31 | $5.15 Million | +110.63% |
| 2003-12-31 | $2.44 Million | +43.65% |
| 2002-12-31 | $1.70 Million | +170100.00% |
| 2001-12-31 | $1.00K | -66.67% |
| 2000-12-31 | $3.00K | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more